Harmony Biosciences (NASDAQ:HRMY) Releases Earnings Results, Beats Expectations By $0.32 EPS

Posted by Brian Himes on Aug 4th, 2026

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $1.28 EPS for the quarter, topping the consensus estimate of $0.96 by $0.32, FiscalAI reports. Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.The business had revenue of $261.28 million for the quarter, compared to analyst estimates of $250.77 million. During the same quarter in the previous year, the company earned $0.92 EPS. The company’s quarterly revenue was up 30.3% on a year-over-year basis.

Here are the key takeaways from Harmony Biosciences’ conference call:

WAKIX sales reached a record $261.3 million in the second quarter, up 30% year over year and 21% sequentially. Harmony reiterated its 2026 net revenue guidance of $1.0 billion to $1.04 billion, supported by strong patient additions and expanded commercial resources.
Harmony reported net income of $75.4 million, or $1.28 per diluted share, versus $39.8 million, or $0.68 per share, a year earlier. The company ended the quarter with approximately $962.5 million in cash and investments, providing substantial capacity for pipeline investment and acquisitions or licensing deals.
Early Phase I data for BP-205 showed rapid absorption, an approximately 25-hour half-life supporting potential once-daily dosing, predictable exposure, and no serious or severe adverse events in the single-ascending-dose study. Harmony plans multiple ascending-dose data in the fourth quarter, an efficacy-focused study readout in early 2027, and Phase II trials across multiple CNS indications beginning in mid-2027.
The pipeline continues to advance, including acceptance of the pitolisant GR NDA with an April 2027 PDUFA date and ongoing Phase III programs for pitolisant HD, Prader-Willi syndrome, and epilepsy. Several key readouts are now expected in 2027, extending the company’s development timeline.
Harmony said it has settled with six of seven WAKIX generic filers and expects patent protection through March 2030, but litigation remains active with the final filer. Management is confident in its position, although the outcome of the remaining proceedings could affect WAKIX exclusivity.

Harmony Biosciences Trading Up 11.5%

NASDAQ HRMY traded up $4.08 during mid-day trading on Tuesday, reaching $39.68. 347,832 shares of the stock were exchanged, compared to its average volume of 849,479. The stock has a market capitalization of $2.30 billion, a PE ratio of 15.96, a PEG ratio of 0.33 and a beta of 0.96. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.56 and a current ratio of 3.58. Harmony Biosciences has a 1-year low of $25.52 and a 1-year high of $40.87. The business’s fifty day simple moving average is $34.59 and its 200 day simple moving average is $32.52.

Analysts Set New Price Targets

A number of brokerages have issued reports on HRMY. Weiss Ratings upgraded shares of Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, June 23rd. Truist Financial increased their price target on shares of Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a research report on Friday, May 8th. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of Harmony Biosciences in a research note on Thursday, July 16th. Mizuho raised their price objective on shares of Harmony Biosciences from $50.00 to $51.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Harmony Biosciences from $30.00 to $36.00 and gave the stock a “hold” rating in a research report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Harmony Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $42.62.

Read Our Latest Stock Analysis on Harmony Biosciences

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. National Bank of Canada FI acquired a new position in Harmony Biosciences in the third quarter valued at $40,000. Kestra Advisory Services LLC acquired a new stake in shares of Harmony Biosciences in the fourth quarter worth approximately $47,000. PNC Financial Services Group Inc. grew its holdings in Harmony Biosciences by 30.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,663 shares of the company’s stock valued at $100,000 after purchasing an additional 619 shares during the period. Tower Research Capital LLC TRC increased its position in Harmony Biosciences by 338.9% during the second quarter. Tower Research Capital LLC TRC now owns 3,511 shares of the company’s stock worth $111,000 after purchasing an additional 2,711 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in Harmony Biosciences during the second quarter worth approximately $120,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

About Harmony Biosciences

(Get Free Report)

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.